TD Cowen lowered the firm’s price target on Insmed (INSM) to $241 from $269 and keeps a Buy rating on the shares. The firm noted its Ph2 brenso BiRCh trial in CRSsNP missed the 1st and 2nd endpoints. CRSsNP represented a small percentage of the company’s value, but Cowen sees continued upside driven by brenso’s NCFBE launch, TPIP Ph3 programs across PAH, PH-ILD and IPF, and pipeline expansion and progress.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target lowered to $203 from $214 at BofA
- Insmed price target lowered to $195 from $215 at RBC Capital
- Insmed price target lowered to $225 from $258 at Goldman Sachs
- Insmed price target lowered to $221 from $230 at Guggenheim
- Maintaining Buy on Insmed: Brensocatib Setback Offset by Strong Brinsupri Launch, Diversified Pipeline, and Near-Term Catalysts